^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Xeljanz XR (tofacitinib XR)

    i
    Other names: Cp-690,550 XR, CP-690550 XR
    Company:
    Pfizer
    Drug class:
    JAK inhibitor
    Related drugs:
    1m
    Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications (clinicaltrials.gov)
    P1/2, N=10, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | Enrolling by invitation --> Completed | N=20 --> 10 | Trial completion date: Jan 2027 --> May 2026 | Trial primary completion date: Jan 2027 --> May 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    Xeljanz XR (tofacitinib XR) • tofacitinib
    2ms
    ChronIA001: Comparing the effectiveness of tofacitinib extended release (XR) chronotherapy, morning versus evening dosing, in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients from a patient's, clinical as well as a translational point of view. (2024-517865-17-01)
    P4, N=84, Recruiting, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Xeljanz XR (tofacitinib XR)
    5ms
    Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications (clinicaltrials.gov)
    P1/2, N=20, Enrolling by invitation, National Institute of Allergy and Infectious Diseases (NIAID) | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial primary completion date
    |
    Xeljanz XR (tofacitinib XR) • tofacitinib
    7ms
    XRPMS: Korean Post-marketing Surveillance for Xeljanz XR (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Pfizer | Trial completion date: Dec 2026 --> Jun 2026 | Trial primary completion date: Dec 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    Xeljanz XR (tofacitinib XR)
    2years
    XRPMS: Korean Post-marketing Surveillance for Xeljanz XR (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Pfizer | Trial completion date: Jun 2024 --> Dec 2026 | Trial primary completion date: Jun 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Xeljanz XR (tofacitinib XR)
    2years
    Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus (clinicaltrials.gov)
    P1, N=7, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting --> Completed | N=10 --> 7
    Trial completion • Enrollment change
    |
    Xeljanz XR (tofacitinib XR) • tofacitinib
    over2years
    XRPMS: Korean Post-marketing Surveillance for Xeljanz XR (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Pfizer | Trial completion date: May 2025 --> Jun 2024 | Trial primary completion date: May 2025 --> Jun 2024
    Trial completion date • Trial primary completion date
    |
    Xeljanz XR (tofacitinib XR)
    over2years
    Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Mar 2024
    Enrollment closed • Trial completion date
    |
    Xeljanz XR (tofacitinib XR) • tofacitinib